Investment Rating - The investment rating for the company is "Buy" (maintained) [2] Core Insights - The company reported a revenue of 1.671 billion yuan for the first half of 2025, representing a year-on-year increase of 15.68%. The net profit attributable to shareholders was 309 million yuan, up 24.74% year-on-year [5] - The sales volume of long-chain dicarboxylic acid products reached a historical high, with significant growth in the production of bio-based sebacic acid [6] - The company has made significant progress in the commercialization of bio-based PA, aiming to become a leading supplier of bio-based piperidine in China [8] - The company is collaborating with CATL to produce bio-based battery shells, which will enhance its presence in the new energy battery sector [7] Financial Performance - In Q2 2025, the company achieved a revenue of 895 million yuan, a year-on-year increase of 17.80% and a quarter-on-quarter increase of 15.37%. The net profit attributable to shareholders was 172 million yuan, up 20.77% year-on-year and 25.39% quarter-on-quarter [5] - The gross profit margin for long-chain dicarboxylic acid products was 42.59%, an increase of 3.27 percentage points year-on-year [6] - The company expects net profits for 2025-2027 to be 686 million, 849 million, and 1.122 billion yuan, with year-on-year growth rates of 40.2%, 23.8%, and 32.1% respectively [9] Market Position and Future Outlook - The company has established itself as a mainstream supplier of bio-based sebacic acid, with a production capacity of 40,000 tons per year [6] - The bio-based PA market is projected to grow, with the company making strides in product development and gaining recognition from major industry clients [8] - The company is expected to maintain a strong growth trajectory, with a projected PE ratio of 54, 44, and 33 for the years 2025, 2026, and 2027 respectively [9]

Investment Rating - The industry investment rating is "Overweight" [1] Core Insights - The chemical sector's overall performance ranked 15th this week, with a change of 2.86%, underperforming the Shanghai Composite Index by 0.63 percentage points and the ChiNext Index by 3.00 percentage points [4][22] - The chemical industry is expected to continue its trend of differentiated performance in 2025, with recommendations to focus on synthetic biology, pesticides, chromatography media, sweeteners, vitamins, light hydrocarbon chemicals, COC polymers, and MDI [4] Industry Performance - The chemical sector's performance for the week of August 18-22, 2025, showed a 2.86% increase, while the Shanghai Composite Index increased by 3.49% and the ChiNext Index by 5.85% [4][22] - The top three performing sub-sectors were other rubber products (8.53%), polyurethane (6.34%), and titanium dioxide (5.69%), while the bottom three were synthetic resin (-1.67%), carbon black (-1.00%), and other plastic products (-0.34%) [23][22] Key Industry Dynamics - South Korea plans to cut naphtha cracking capacity by 25%, affecting 2.7 to 3.7 million tons based on an annual capacity of 14.7 million tons, as part of efforts to restructure its petrochemical industry [35] - The Ministry of Industry and Information Technology of China held a meeting to regulate the photovoltaic industry, emphasizing the importance of maintaining a healthy competitive environment [35] Recommended Focus Areas - Synthetic biology is highlighted as a key area for growth, with traditional chemical companies needing to adapt to energy costs and carbon taxes [4] - The third-generation refrigerants are expected to enter a high-growth cycle due to supply constraints and increasing demand from markets like Southeast Asia [5] - The electronic specialty gases market presents significant opportunities for domestic companies due to high technical barriers and increasing demand from semiconductor and photovoltaic sectors [6][8] - Light hydrocarbon chemicals are becoming a global trend, with a shift towards lighter raw materials for ethylene production [8] - The COC polymer industry is accelerating its domestic industrialization process, driven by supply chain security concerns [9] - Potash fertilizer prices are expected to rebound as major producers reduce output and demand increases from farmers [10] - The MDI market is characterized by oligopoly, with a favorable supply structure anticipated as demand recovers [12]

Company Overview - Kasei Biotech Co., Ltd. is located at 396 Lane 11, Oasis Ring Road, Minhang District, Shanghai, established on November 24, 2000, and listed on August 12, 2020 [1] - The company specializes in synthetic biology and related fields, classified under the basic chemical industry, specifically in chemical products and other chemical products [1] Stock Performance - As of August 22, Kasei Biotech's stock price increased by 2.01%, reaching 51.70 CNY per share, with a trading volume of 64.04 million CNY and a turnover rate of 0.22%, resulting in a total market capitalization of 37.29 billion CNY [1] - Year-to-date, the stock price has risen by 34.63%, with a 5-day increase of 5.34%, a 20-day increase of 6.62%, and a 60-day increase of 9.67% [1] Financial Performance - For the period from January to June 2025, Kasei Biotech reported a revenue of 1.671 billion CNY, reflecting a year-on-year growth of 15.68% [2] - The company has distributed a total of 1.023 billion CNY in dividends since its A-share listing, with 503 million CNY distributed over the past three years [2] Shareholder Information - As of June 30, 2025, Kasei Biotech had 11,700 shareholders, a decrease of 2.87% from the previous period, with an average of 49,801 circulating shares per shareholder, an increase of 2.95% [2] - Among the top ten circulating shareholders, the Huaxia SSE Sci-Tech Innovation Board 50 ETF (588000) ranked as the eighth largest shareholder, holding 19.85 million shares, an increase of 3.46 million shares from the previous period [2]

Investment Rating - The report maintains a "Strong Buy" rating for the company, indicating an expectation to outperform the benchmark index by over 20% in the next six months [1][17]. Core Insights - The company reported significant growth in Q2, with a year-on-year revenue increase of 17.80% and a quarter-on-quarter increase of 15.37%. The net profit for Q2 also saw a year-on-year rise of 20.77% and a quarter-on-quarter increase of 25.39% [7]. - The company is a leader in the long-chain dicarboxylic acid industry, with a strong focus on bio-based materials. It has established a production capacity of 115,000 tons for bio-based long-chain dicarboxylic acids and is expanding its product offerings [7]. - The company has increased its R&D investment, with a 23.1% year-on-year rise in R&D expenses, reflecting its commitment to developing a leading bio-based materials industry chain [7]. Financial Performance Summary - For 2025, the company is projected to achieve total revenue of 35.47 billion yuan, representing a year-on-year growth of 19.9%. The net profit is expected to reach 6.83 billion yuan, with a growth rate of 39.7% [2][8]. - The earnings per share (EPS) for 2025 is estimated at 0.95 yuan, with a price-to-earnings (P/E) ratio of 53.2 times [2][8]. - The company’s total assets are projected to grow to 25.35 billion yuan by 2025, with a debt-to-equity ratio of 6.7% [8]. Market Position and Strategy - The company is actively promoting its bio-based composite materials across various sectors, including textiles and engineering materials, and is developing new applications in renewable energy and automotive components [7]. - The establishment of new subsidiaries indicates the company's strategy to create an integrated bio-based materials industry chain, enhancing its market competitiveness [7].

Group 1 - The stock price of Kaisa Biotech closed at 50.89 yuan on August 19, 2025, down by 1.03 yuan, a decrease of 1.98% from the previous trading day [1] - The trading volume on that day was 45,800 lots, with a total transaction value of 235 million yuan [1] - Kaisa Biotech operates in the chemical products industry, focusing on the research, production, and sales of bio-based materials, which are widely used in textiles and engineering plastics [1] Group 2 - Kaisa Biotech is listed on the Sci-Tech Innovation Board and has been included in the list of specialized and innovative enterprises [1] - On August 18, 2025, the company held an extraordinary general meeting to elect members of the third board of directors, and the appointment of senior management was completed the following day [1] - On August 19, there was a net outflow of 15.65 million yuan in main funds, with a cumulative net outflow of 47.84 million yuan over the past five days [1]

Core Viewpoint - Kasei Biotech announced the convening of its second extraordinary general meeting of shareholders in 2025 on August 18, 2025, to elect members of the third board of directors [2] Group 1 - The company will hold its third board of directors' first meeting the following day to elect the chairman, vice chairman, and members of various specialized committees, as well as appoint senior management personnel [2]

Core Viewpoint - The fourth Synthetic Biology and Green Bio-Manufacturing Conference (SynBioCon 2025) will focus on four main directions: AI + Bio-Manufacturing, Green Chemistry and New Materials, Future Food, and Future Agriculture [2]. Group 1: Conference Overview - The conference will take place from August 20-22 at the Sheraton Hotel in Donggang, Ningbo, Zhejiang [2][3]. - Various activities will be held concurrently, including a Youth Forum on Bio-Manufacturing, a high-level discussion on the bio-manufacturing industry, and a closed-door seminar for the "2025 AI Empowering Bio-Manufacturing Industry Innovation Development Blue Book" [2][12]. Group 2: Event Schedule - Registration will occur on August 20 from 12:00 to 20:00 and on August 21 from 8:50 to 12:00, where attendees will receive conference materials [7]. - The opening ceremony and macro forum for the bio-manufacturing industry will be held on August 21, followed by specialized forums on green chemistry and AI applications in bio-manufacturing [10][19]. Group 3: Supporting Organizations - The conference is organized by Ningbo Detaizhong Research Information Technology Co., Ltd. and supported by various institutions, including Peking University Ningbo Institute of Ocean Medicine and the Ningbo Enzyme Science Bioengineering Co., Ltd. [4][5]. - Strategic media partners and numerous experts from various universities and companies will also participate [5][12]. Group 4: Accommodation and Transportation - Attendees can enjoy special rates at the conference hotel, with prices starting at 400 RMB per night for a standard room [9]. - Transportation options from Ningbo Lishe International Airport and Ningbo Railway Station to the hotel are available, with estimated travel times and costs provided [8]. Group 5: Weather Forecast - The weather forecast for the conference days indicates mostly sunny to partly cloudy conditions, with temperatures ranging from 27°C to 38°C [8]. Group 6: Key Topics and Innovations - The conference will feature discussions on innovative topics such as the synthesis of bio-based carboxylic acids, the application of enzyme molecular engineering, and the design of humanized "4D" collagen proteins [14][38]. - Presentations will also cover advancements in the production of functional sugars, microalgae-based selenium proteins, and the biomanufacturing of natural terpenoids [37][38].

Investment Rating - The report maintains an "Outperform" rating for the company [1] Core Insights - The company reported a revenue of 1.671 billion yuan for H1 2025, reflecting a year-on-year growth of 16% and a net profit of 309 million yuan, up 25% year-on-year [8] - The sales volume of long-chain dicarboxylic acids, particularly sebacic acid, reached a historical high, with the company maintaining a global leading position in this product line [8] - The company is actively building an ecosystem for bio-based polyamide and its composite materials, with several strategic partnerships and projects underway to enhance production capacity and market reach [8] Financial Data and Profit Forecast - Total revenue projections for 2025 are estimated at 3.539 billion yuan, with a year-on-year growth rate of 19.6% [7] - The forecasted net profit for 2025 is 648 million yuan, representing a year-on-year increase of 32.4% [7] - The company's gross margin for Q2 2025 was reported at 34.03%, showing a slight increase compared to previous periods [8]

证券代码：688065 证券简称：凯赛生物 公告编号：2025-046 上海凯赛生物技术股份有限公司 关于完成董事会换届选举、聘任高级管理人员的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 根据《中华人民共和国公司法》（以下简称"《公司法》"）、《上海证券交 易所科创板股票上市规则》（以下简称"《上市规则》"）、《上海证券交易所科创板 上市公司自律监管指引第 1 号——规范运作》等法律、法规、规范性文件及《上 海凯赛生物技术股份有限公司章程》（以下简称"《公司章程》"）等有关规定，上 海凯赛生物技术股份有限公司（下称"公司"）于 2025 年 8 月 18 日召开 2025 年第二次临时股东大会，选举产生第三届董事会成员。次日，公司召开第三届董 事会第一次会议，选举产生董事长、副董事长、各专门委员会委员及召集人，并 聘任高级管理人员。现将相关情况公告如下： 国证券监督管理委员会、证券交易所处罚的情形。其中董事会秘书臧慧卿女士已 取得上海证券交易所颁发的《科创板董事会秘书资格证书》，且其任职资格已经 通过上海证券交易 ...

Core Viewpoint - Kasei Biotech (688065.SH), recognized as the "first synthetic biology stock" on the STAR Market, has shown continuous growth in its operating performance, with significant increases in both revenue and net profit in the first half of 2025 [1][2] Financial Performance - In the first half of 2025, Kasei Biotech achieved total revenue of 1.671 billion yuan, representing a year-on-year growth of 15.68%, and a net profit of 309 million yuan, up 24.74% year-on-year [1][2] - The company's revenue has grown from 1.497 billion yuan in 2020 to 2.958 billion yuan in 2024, marking a 97.6% increase over the period [2] - In 2024, the core product, long-chain dicarboxylic acid series, generated revenue of 2.670 billion yuan, with a growth rate of 39.94% [3] Research and Development - Kasei Biotech has invested a total of 951 million yuan in R&D from 2020 to the first half of 2025, with a consistent increase in annual investment [4] - The company has obtained a total of 516 patents by the end of the first half of 2025, with 77.5% being invention patents, which strengthens its technological barriers [5][6] Asset Growth and Capital Operations - As of the end of the first half of 2025, Kasei Biotech's total assets reached 23.82 billion yuan, a 30.02% increase compared to the same period last year [1][6] - The company successfully raised 5.915 billion yuan through a private placement to fund the second phase of its 900,000-ton bio-based polyamide project and upgrade its R&D center [6]